China Biologic Products (NASDAQ: CBPO) is one of 285 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare China Biologic Products to related companies based on the strength of its earnings, dividends, institutional ownership, analyst recommendations, valuation, profitability and risk.
Earnings and Valuation
This table compares China Biologic Products and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|China Biologic Products||$341.17 million||$104.77 million||19.76|
|China Biologic Products Competitors||$284.28 million||$34.29 million||133.11|
Insider and Institutional Ownership
65.7% of China Biologic Products shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 2.7% of China Biologic Products shares are owned by insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Risk & Volatility
China Biologic Products has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500. Comparatively, China Biologic Products’ competitors have a beta of 0.53, suggesting that their average stock price is 47% less volatile than the S&P 500.
This is a summary of recent recommendations for China Biologic Products and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|China Biologic Products||0||1||2||0||2.67|
|China Biologic Products Competitors||851||3198||11598||231||2.71|
China Biologic Products presently has a consensus price target of $137.50, suggesting a potential upside of 75.32%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 45.54%. Given China Biologic Products’ higher possible upside, equities analysts clearly believe China Biologic Products is more favorable than its competitors.
This table compares China Biologic Products and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|China Biologic Products||31.29%||21.49%||18.58%|
|China Biologic Products Competitors||-5,277.49%||-435.66%||-39.69%|
China Biologic Products beats its competitors on 8 of the 13 factors compared.
About China Biologic Products
China Biologic Products Holdings, Inc. is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.The Company’s products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).
What are top analysts saying about China Biologic Products Holdings Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for China Biologic Products Holdings Inc. and related companies.